Previous 10 | Next 10 |
Moleculin Biotech launches a public offering of common stock. Price, volume and terms have yet to be announced. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ...
HOUSTON , March 26, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it intends to offer and sell unit...
March 26, 2019 Palm Beach, FL – March 26, 2019 – Research for the cure for cancer has become this generation’s version of President John F. Kennedy’s May 25, 1961 proclamation to “… landing a man on the Moon and returning him safely”. ...
Moleculin Biotech (NASDAQ: MBRX ) announces positive interim safety and efficacy data from two ongoing Phase 1/2 studies of Annamycin. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ...
March 26, 2019 Palm Beach, FL – March 26, 2019 – At present, medical practitioners have few options when they are presented with a patient with leukemia. The Leukemia & Lymphoma Society’s website points out that : “It’s important that your doctor ...
HOUSTON , March 26, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced positive interim safety and efficacy d...
HOUSTON , March 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the first two patients have been ...
HOUSTON , March 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Dr. Martin Tallman , Chief of Le...
HOUSTON , March 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of...
March 14, 2019 Palm Beach, FL – March 14, 2019 – According to the Leukemia & Lymphoma Society, the world’s largest voluntary health agency dedicated to blood cancer, In 2018, 60,300 people are expected to be diagnosed with leukemia and that there are an estimat...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.7% to $109.21 on volume of 508,402,989 shares Redhill Biopharma Ltd. (RDHL) rose 97.9% to $0.76 on volume of 355,380,053 shares PROSHARES TRUST (SQQQ) rose 7.3% to $9.22 on volume of 284,777,109 shares ...
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial PR Newswire Based on an encouraging discussion in the End of Phase 1B /2 Meeting with FDA the Company plans to: Proceed with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for po...
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...